Biosidus, an Argentina-based biotechnology company, announced on Wednesday the signing of a licensing and supply agreement with Mubadala Bio, the life sciences platform of Mubadala Investment Company, to introduce a portfolio of biologic therapies in the United Arab Emirates through DiabTec, Mubadala Bio's biologics platform.
The collaboration includes biologic therapies across endocrinology, nephrology and oncology, including epoetin alfa, filgrastim, interferon beta and somatropin.
The agreement was signed during BIO International Convention 2026.
Oncoinvent reports recruitment milestone in Phase 2 study of Radspherin in ovarian cancer
FDA accepts Genentech application for Lunsumio and Polivy combination in large B-cell lymphoma
Getinge launches Fluobeam LS for fluorescence‑guided small‑incision surgery
Organon and Samsung Bioepis expand Canada biosimilar partnership with PYZCHIVA
Niowave and Ratio Therapeutics agree Actinium-225 supply deal for targeted alpha therapies
Minghui Pharmaceutical presents MHB018A Phase I/II results for thyroid eye disease at ENDO 2026
Lonza and Antharis Therapeutics enter target-specific licence agreement
Inhibrx's ozekibart BLA accepted by FDA for chondrosarcoma treatment
AstraZeneca secures US approval for Truqap combination in PTEN‑deficient prostate cancer
Menarini reports Phase 3 data for selinexor plus ruxolitinib in myelofibrosis
Roche secures IVDR approval to expand VENTANA MMR RxDx Panel indications
Guardant Health expands FDA-approved companion diagnostic use for HERNEXEOS